Mauldin, Ileana S.
Wages, Nolan A.
Stowman, Anne M.
Wang, Ena
Smolkin, Mark E.
Olson, Walter C.
Deacon, Donna H.
Smith, Kelly T.
Galeassi, Nadedja V.
ChianeseāBullock, Kimberly A.
Dengel, Lynn T.
Marincola, Francesco M.
Petroni, Gina R.
Mullins, David W.
Slingluff, Craig L. Jr. http://orcid.org/0000-0002-6664-4373
Funding for this research was provided by:
National Institutes of Health (NIH/NCI R01 CA134799, NIH/NCI grant K25 CA181638, NIH/NCI P30 CA44579)
Article History
Received: 7 March 2016
Accepted: 11 July 2016
First Online: 13 August 2016
Compliance with ethical standards
:
: Craig Slingluff is an inventor of several peptides included in the vaccine that was administered during the clinical trials studied within this paper. The University of Virginia Licensing and Ventures Group holds the patents for those peptides, which have been licensed through the Ludwig Institute for Cancer Research to GlaxoSmithKline. He also has relationships with several commercial interests related to this work, including Immatics (member, Scientific Advisory Board), Polynoma (principal investigator for MAVIS cancer vaccine trial), GlaxoSmithKline (recipient of grant support for a clinical trial), but funds from those relationships go to the University of Virginia, and not to Dr. Slingluff personally. The remaining authors have nothing to disclose or competing interests in association with this study.